133 related articles for article (PubMed ID: 2795118)
1. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Yung WK; Harris MI; Bruner JM; Feun LG
J Neurooncol; 1989 Sep; 7(3):237-40. PubMed ID: 2795118
[TBL] [Abstract][Full Text] [Related]
2. Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Schold SC; Mahaley MS; Vick NA; Friedman HS; Burger PC; DeLong ER; Albright RE; Bullard DE; Khandekar JD; Cairncross JG
J Clin Oncol; 1987 Mar; 5(3):464-71. PubMed ID: 3029339
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Schold SC; Herndon JE; Burger PC; Halperin EC; Vick NA; Cairncross JG; Macdonald DR; Dropcho EJ; Morawetz R; Bigner DD
J Clin Oncol; 1993 Jan; 11(1):77-83. PubMed ID: 8418246
[TBL] [Abstract][Full Text] [Related]
4. Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma. Preliminary results.
Calvo FA; Pastor MA; Dy C; Alegría E; Antón Aparicio LM; Gil A; Harguindey S; Zubieta JL; Martinez Lage M
Am J Clin Oncol; 1985 Jun; 8(3):200-9. PubMed ID: 4050738
[TBL] [Abstract][Full Text] [Related]
5. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Halperin EC; Gaspar L; Imperato J; Salter M; Herndon J; Dowling S
Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Brandes AA; Scelzi E; Zampieri P; Rigon A; Rotilio A; Amista P; Berti F; Fiorentino MV
Am J Clin Oncol; 1997 Aug; 20(4):364-7. PubMed ID: 9256890
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL
Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
Chamberlain MC; Prados MD; Silver P; Levin VA
J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
[TBL] [Abstract][Full Text] [Related]
10. Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Mack F; Schäfer N; Kebir S; Stuplich M; Schaub C; Niessen M; Scheffler B; Herrlinger U; Glas M
Oncology; 2014; 86(5-6):369-72. PubMed ID: 24942787
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas.
Yerram P; Reiss SN; Modelevsky L; Gavrilovic IT; Kaley T
J Neurooncol; 2019 Oct; 145(1):57-63. PubMed ID: 31432377
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
Smith DC; Vick NA; Trump DL; Friedman HS; Friedman AH; Purvis J; Gauspari A; Schold SC
Cancer Chemother Pharmacol; 1992; 30(4):272-6. PubMed ID: 1643694
[TBL] [Abstract][Full Text] [Related]
16. Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study.
Balmaceda C; Fetell MR; Hesdorffer C
Cancer Chemother Pharmacol; 1997; 40(1):72-4. PubMed ID: 9137533
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Reid JM; Bagniewski PJ; Ames MM; Cascino TL; Marks RS
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):969-75. PubMed ID: 9869217
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.
Galanis E; Buckner JC; Burch PA; Schaefer PL; Dinapoli RP; Novotny PJ; Scheithauer BW; Rowland KM; Vukov AM; Mailliard JA; Morton RF
J Clin Oncol; 1998 Sep; 16(9):2953-8. PubMed ID: 9738563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
